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EDITORIAL

The AKI Clinic for Fragile Patients

T

he recent terrorist attack in Manchester, England, at a
pop “musical” concert1 represents a somber reminder
of the London Blitz—the “lightning war”—prosecuted
by Hitler against Great Britain during World War II.
The dome of the church on the cover illustration, provided by Guest Editor, Charuhas Thakar, represents the
hope of the Londoners who survived the protracted
bombing that lasted 9 months, and our own hope that
an effective resolution to the
abject, lawless acts of violence
by fanatical and radical terrorists
comes soon.
Nephrologists are well acquainted with the physical repercussions of bombing. During the
Blitz, muscle “crush” injuries
from entrapment under the
rubble of destroyed buildings
led to oliguric kidney failure,
eloquently described by Bywaters
and Beall.2 Without the extant
technologies of kidney replacement that are commonplace in
contemporary nephrology, those who did not experience
rapid recovery of kidney function died a uremic death.
From the clinical observations of the Blitzkrieg victims,
Bywaters and Beall formulated the construct of
myoglobin-induced acute kidney injury (AKI), Bywaters
and colleagues subsequently developed 2 animal models
of rhabdomyolysis-induced AKI that still serve as touchstones for all clinician scientists. One involved injection
of crystalline myoglobin3 and the other a controlled
muscular crush injury.4 Indeed, the scientiﬁc inquiry
into pigmentary nephropathy via the subsequently
developed rodent model of glycerol-induced rhabdomyolysis greatly advanced the knowledge base of AKI.
These advances were followed by more comprehensive
analyses of rhabdomyolysis-induced AKI and have elucidated that nearly all mechanisms of AKI are at play,
including ischemic, toxic, cytokine mediated, among
others.
Despite advances in our understanding of AKI pathophysiology, we remain naïve in many areas, including even

appropriate follow-up of AKI survivors. We are painfully
reminded of exacerbation of the folly of “crash” dialysis
that followed the Centers for Medicare and Medicaid Services (CMS) rescinding of immediate availability of incenter dialysis for AKI patients. A “shot across the bow”
had been issued as CMS Change Request 7762 on April
26, 2012.5 The gist of this request was that AKI inpatients
bound for outpatient, in-center hemodialysis centers would
be stranded, and this onerous
“ﬁnal rule” would become effective October 1, 2012. Afterward,
nearly all US nephrologists were
left scrambling to establish “AKI
clinics” for their newly minted hemodialysis patients, the majority
of which would require dialysis
for more than 90 days and
become baptized as ESRD patients. What happens to AKI
patients who are dialysis dependent (AKI-D) at the time of
discharge? Before 2012, the solutions to this scenario were simple.
AKI-D patients would either remain in the hospital until recovery of kidney function or be discharged to dialyze in an
ESRD in-center hemodialysis center. This instantaneous
transition to an outpatient hemodialysis in-center unit was
efﬁcient but generally not tailored to the care of the AKI patient. Typically, the patient would have had minimal, if any,
education regarding either AKI or CKD, much less ESRD.
Informational overload within the relatively noisy, nonprivate setting of an in-center hemodialysis center would
ensue. Patient engagement was consequently highly variable and compounded by noise, language, and cultural barriers, and possibly ineffective instructional methods in the
busy, outpatient dialysis environment. Medical care for the
AKI-D patient may also differ from that of the ESRD
population.
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The practice of transitioning a patient to an in-center facility after dialysis-dependent AKI had never been CMS
sanctioned. All nephrologists did it, and CMS ignored
the practice until the expense of AKI became costly. To
provide dialytic services, “AKI clinics” were rapidly implemented for AKI-D patients in response to the reversal
of CMS’ policy. These clinics were essentially in-center
dialysis units embedded in the majority of participating
hospitals. Although some centers treated AKI patients
with protocols that required greater infrastructure, more
intensive monitoring, and an overall greater level of
care, this practice was not uniformly adopted. This stopgap measure inconvenienced patients and providers, but
provided life-sustaining therapy. Now that CMS once
again permits the direct transition of AKI-D patients to
in-center dialysis units, that problem is resolved. However, there is still the issue of vital education of patients
regarding AKI, CKD, modality choice, and nutritional
advice, which may not be delivered in a timely fashion
and begs the question: “How, when, and where will this
occur?”
Fortunately, most of those who develop an episode of
AKI do not develop oliguric kidney failure and die a uremic death or require kidney replacement therapy. The minority who do develop an episode of severe AKI
necessitating acute kidney replacement therapy require
intense follow-up for signs of kidney recovery.6 AKI
may foster the development of CKD, particularly when
severe.7 An episode of AKI also may test the kidney
fragility of patients with preexistent CKD. CKD may be
unmasked by the kidney stressor of AKI. Fortunately,
not every episode of AKI leads to CKD, and prediction
of CKD after AKI remains a difﬁcult enterprise. Prediction
of risk of dialysis in CKD has been validated by Tangri
and colleagues,8 and the prediction of requirement for
dialysis during AKI is possible by a 4- or 8-variable Kidney Failure Risk Equation.9 However, determination of
the exact downward trajectory of GFR as espoused by
Cerd
a and colleagues6 requires multiple GFR measurements and evaluation points over several years. Therefore,
to optimize the care of AKI patients with uncertain renal
futures, periodic follow-up is obligatory.
How and where should AKI follow-up be ensured?
For AKI patients who are not dialysis dependent at
discharge, the old standby of “labs in one week with
PCP, call with questions” is not optimal. Early
nephrology follow-up (within 90 days of discharge)
was associated with decreased mortality for AKI-D patients who had recovered sufﬁcient kidney function to
stop dialysis before discharge.10 How to implement a
clinical system that facilitates this careful follow-up is
a challenge. Tracking AKI-D patients as they transition
from the inpatient to outpatient setting, and ﬁnding
time and staff in clinic to track and follow these patients, requires an innovative approach. Two groups of
AKI-D patients, those who remain on dialysis at
discharge and those who have recovered sufﬁcient kidney function to stop dialysis by the time of discharge,

will most likely be in separate health care systems,
one in the outpatient dialysis arena and the other in
ambulatory clinics. Electronic health record systems
could facilitate the identiﬁcation of patients, but this
will require information technology expertise and staff
to generate meaningful tracking tools across different
health record platforms. Leadership by nephrologists
is critical for success of AKI (and CKD) information
technology as AKI is a global problem that has changed
the climate of kidney care. The infrastructure for success
should be built into standard clinical care and not by
successful applications for grant funding.
Interdisciplinary (ID) CKD clinics are a logical place to
coordinate follow-up,11 particularly because recovering
AKI patients are at risk for the development of CKD
and CKD patients are themselves at risk for AKI. Additionally, nephrology advanced practice providers
frequently care for patients in both systems—the outpatient dialysis units and the ambulatory clinics—and,
thus, may augment continuity of care as patients move
between systems. Many of the same renal-protective
educational and therapeutic interventions are the same
as those already implemented for CKD patients.11 However, advanced practice providers may require additional
education and guidance from the nephrologist in the
management of resolving dialysis-dependent AKI.
More frequent labs (requiring prompt interpretation for
recovery of kidney function) may be ordered. It is unclear how applicable ESRD quality indicators are for
AKI care. These indicators are unproven as beneﬁcial
in AKI, and should not be instituted as quality measures
for this population. These patients may require a
different approach to volume management, avoiding
aggressive ultraﬁltration to limit hypotensive episodes
that may further exacerbate kidney injury.12,13 As time
progresses, and the chance of renal recovery wanes,
patients will need education regarding modality,
transplant, and access. At some point, patients with
AKI who remain dialysis dependent may need a
change in status to ESRD. Coordinating this through
AKI-extended ID CKD clinics may address many of
these needs. Primary care physicians should also be
included in the follow-up process as they will be
following these at-risk patients long-term and will be
on the front lines of prevention and detection of subsequent AKI and CKD.
How do we move forward? AKI carries a tremendous
burden, including the increased risk of dying. A simple
program of early nephrology clinic visits may help to
mitigate that risk.10 These tools are already available
in the ID CKD clinic and can help to facilitate optimal
kidney recovery or a smooth transition to ESRD for
those who do not recover kidney function. The key to
optimizing outcomes is simple. The patient must be followed and carefully. ID CKD clinics14—not new AKI
clinics—can be extended in scope and suitably resourced and represent one solution for our fragile AKI
patients.
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If blood will ﬂow when ﬂesh and steel are one
Drying in the color of the evening sun
Tomorrow’s rain will wash the stains away
But something in our minds will always stay

2.

Perhaps this ﬁnal act was meant
To clinch a lifetime’s argument
That nothing comes from violence and nothing
ever could

4.

3.

5.

For all those born beneath an angry star
Lest we forget how fragile we are
6.

—Fragile, Gordon Sumner (1987)
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